Abstract
A number of highly promiscuous seven transmembrane (7TM) receptors have been cloned and characterized within the last few years. It is noteworthy that many of these receptors are activated broadly by amino acids, proteolytic degradation products, carbohydrates, or free fatty acids and are expressed in taste tissue, the gastrointestinal tract, endocrine glands, adipose tissue, and/or kidney. These receptors thus hold the potential to act as sensors of food intake, regulating, for example, release of incretin hormones from the gut, insulin/glucagon from the pancreas, and leptin from adipose tissue. The promiscuous tendency in ligand recognition of these receptors is in contrast to the typical specific interaction with one physiological agonist seen for most receptors, which challenges the classic “lock-and-key” concept. We here review the molecular mechanisms of nutrient sensing of the calcium-sensing receptor, the G protein-coupled receptor family C, group 6, subtype A (GPRC6A), and the taste1 receptor T1R1/T1R3, which are sensing l-α-amino acids, the carbohydrate-sensing T1R2/T1R3 receptor, the proteolytic degradation product sensor GPR93 (also termed GPR92), and the free fatty acid (FFA) sensing receptors FFA1, FFA2, FFA3, GPR84, and GPR120. The involvement of the individual receptors in sensing of food intake has been validated to different degrees because of limited availability of specific pharmacological tools and/or receptor knockout mice. However, as a group, the receptors represent potential drug targets, to treat, for example, type II diabetes by mimicking food intake by potent agonists or positive allosteric modulators. The ligand-receptor interactions of the promiscuous receptors of organic nutrients thus remain an interesting subject of emerging functional importance.
Footnotes
- Received January 30, 2009.
- Accepted June 1, 2009.
This work was supported by the Danish Medical Research Council; The UNIK Centre for Life-style Diseases; the Drug Research Academy; the Villum Kann Rasmussen Foundation; the Simon Foughner Hartmanns Familiefond; and the Aase and Ejner Danielsen Foundation.
P.W. and L.D.J. contributed equally to this work.
ABBREVIATIONS: TM, transmembrane; CaR, calcium-sensing receptor; mGlu, metabotropic glutamate; GPRC6A, G protein-coupled receptor family C, group 6, subtype A; T1R, taste1 receptor; VFT, Venus flytrap; CRD, cysteine-rich domain; GI, gastrointestinal; CCK, cholecystokinin; NPS R-568, N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine; NPS 2143, N-(2-hydroxy-3-(2-cyano-3-chlorophenoxy)propyl)-1,1-dimethyl-2-(2-nephthyl)ethylamine; Calhex 231, N(1)-(4-chlorobenzoyl)-N(2)-(1-(1-naphthyl)ethyl)-1,2-diaminocyclohexane; FFA, free fatty acid; GW9508, 4-[[(3-phenoxyphenyl)methyl]amino]benzenepropanoic acid; GLP-1, glucagon-like peptide-1; S807, N-(heptan-4-yl)benzo[d][1,3]dioxole-5-carboxamide; S819, 1-((1H-pyrrol-2-yl)methyl)-3-(4-isopropoxyphenyl)thiourea.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|